Cohort A1

Phase 1

RRebecca Arend

Cohort A1 is one of 7 therapeutic programs targeting Platinum-resistant Ovarian Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Platinum-Resistant Ovarian CancerNot yet recruiting

Platinum-Resistant Ovarian CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

15 competitors in Platinum-Resistant Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

3 2

Avastin

Roche

Phase 3

1 3

SYS6043

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

1 4

N-803

IImmunityBio, Inc.

Phase 2

1 5

Olvimulogene Nanivacirepvec

GGenelux Corporation

Phase 3

1 6

M-CENK

IImmunityBio, Inc.

Phase 2

1 7

Cohort A1

RRebecca Arend

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Not yet recruiting

Platinum-Resistant Ovarian Cancer

NCT07772882

Clinical

Trials by Indication[1]

Platinum-resistant Ovarian Cancer1 trial

Phase I Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

Not yet recruiting·RRebecca Arend·Phase 1·NCT07772882·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cohort A1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cohort A1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Rebecca Arend company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: RRebecca Arend

Cohort A1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Platinum-resistant Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News